O60 Icotrokinra, a targeted oral peptide that blocks IL-23 receptor activation, in moderate-to-severe ulcerative colitis: week 12 results from ANTHEM-UC
Hypoxia is a prevalent characteristic of neurological diseases, including ischemic injury, neurodegeneration and infectious disease complications. Concurrently, hypoxia shapes both protective and pathological responses within the central nervous system (CNS). Central to this process is hypoxia-inducible factor 1α (HIF1α), a transcription factor that regulates cellular adaptation to reduced oxygen availability through coordinated glycolytic, inflammatory and cell survival pathways. Under hypoxic conditions, HIF1α transcriptional activity influences microglial activation, mitochondrial quality control, and cytokine production, thereby modulating neuroinflammation and neuroprotection. Preclinical evidence points toward hypoxia preconditioning being neuroprotective through HIF1α-dependent mechanisms in a context-dependent matter. This review synthesizes the current understanding of the role of HIF1α across neurological disease contexts, highlighting the intersection of hypoxia, neuroinflammation and neuronal survival. Ultimately, defining the cell-specific and context-dependent involvement of HIF1α will be critical for targeted therapeutic approaches to alleviate neuronal death and slow disease progression.
A75-06 Genetic Counselor-Supported DNA Sequencing for Bronchiectasis: A Mayo Clinic Experience With Diagnosis and Management
Abstract Purpose Bronchiectasis is a condition characterized by chronic cough, recurrent infections, and progressive airway damage that is rising in prevalence. While often idiopathic, a subset of patients have a genetic cause such as cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or alpha-1-antitrypsin deficiency (A1ATD). Genetic causes for bronchiectasis should be considered in patients with diffuse bronchiectasis involving ≥2 lobes, especially in those with early onset of symptoms, recurrent otitis media or chronic rhinosinusitis, infertility, organ laterality defects (e.g., situs inversus), exocrine pancreatic insufficiency or family history of bronchiectasis. Genetic testing may impact management decisions. Methods The Mayo Clinic Center for Individualized Medicine developed the Program for Rare and Undiagnosed Diseases (PRaUD) Genetic Testing and Counseling Unit (GTAC) provides abbreviated, point-of-care genetic counseling, and DNA sequencing-based testing. Patients with bronchiectasis evaluated by GTAC underwent exome or genome-based 52-gene panels which included PCD, CF, and A1ATD (SERPINA1)-associated genes. Sequencing panes results were reviewed and interpreted by a multidisciplinary team including genetic counselors, geneticists, and pulmonologists. Results From July 2022 to December 2025, 203 patients were identified; 163 patients completed testing (74% female, 93% white). A molecular diagnosis was confirmed in 10.4% (17/163) of cases, with known pathogenic variants identified in RSPH4A, SERPINA1 (A1ATD), and CFTR (CF). Variants of uncertain significance (VUS) were identified in 24% of patients. Notably, 11.6% (19/163) were identified as CF carriers, a rate significantly higher than the general European-ancestry population (∼4%). Clinical management was impacted for two patients, including the initiation of targeted CFTR modulator therapy in one patient with CF-related disorder (CFTRD) and one CFTR pathogenic variant heterozygote. Conclusions Genetic counselor-supported DNA sequencing for bronchiectasis led to an increased identification of genes that cause bronchiectasis. Interestingly, we found a high rate of CFTR heterozygote variant carriers in our clinic cohort, this aligns with the findings of other studies that CFTR variant carriers can have an increased frequency of bronchiectasis. The identification of pathogenic variants and VUS helps facilitate a diagnosis or potential genetic cause in a significant proportion of patients and highlights the need for further research in understanding the epidemiology of CF, PCD, and A1ATD-related variant genotypes in patients with bronchiectasis. Clinical Implications Comprehensive DNA sequencing, combined with genetic counseling and support from genetic counselors in partnership with pulmonologists can advance precision diagnostics and care for patients with bronchiectasis. This abstract is funded by: None
C27-20 Pre-transplant Fungal Colonization and Outcomes in Lung Transplant Recipients
Abstract Rationale Fungal infections are a significant cause of morbidity in lung transplant recipients. Infections caused by non-Aspergillus species (spp.) fungi, such as Alternaria, Cladosporium, Fusarium, Lomentospora, Mucorales, and Scedosporium, among others, occur infrequently, but recognized cases are increasing. There is a paucity of data assessing post-transplant outcomes following pre-transplant fungal colonization with these non-Aspergillus spp. fungal organisms. Methods We retrospectively reviewed all adult (>18 years) patients who underwent bilateral lung transplantation at either Mayo Clinic Rochester and Mayo Clinic Jacksonville between 01/01/2016 through 12/31/2024, comparing those with pre-transplant fungal colonization to those without fungal colonization. Fungal colonization was defined as positive respiratory culture in either sputum, tracheal aspirate, bronchial brush, bronchoalveolar lavage (BAL) fluid, or swab of explanted lung in asymptomatic patients without radiological or endobronchial evidence of infection. Patients who underwent single lung transplantation, multi-organ transplantation, and those who had previously undergone organ transplantation were excluded from the study. Our primary outcome was severe post-transplant fungal infection, which we defined as proven or probable invasive fungal infection (based on EORTC/MSG criteria), that required hospitalization or additional procedural intervention. Baseline characteristics were summarized using medians with interquartile ranges or counts with percentages, group balance was assessed using standardized mean differences, and associations with post-transplant fungal infection and mortality were evaluated using unadjusted risk ratios (RR) with 95% confidence intervals. Results Of the 449 lung transplant recipients who were included in analysis, a total of 83 patients (18.5%) had pre-transplant fungal colonization, 45 patients (10.0%) with Aspergillus spp. and 38 patients (8.5%) with non-Aspergillus fungi. Compared to those without pre-transplant fungal colonization (n = 366), those with fungal colonization differed significantly in age, gender, body mass index (BMI), Cytomegalovirus (CMV) mismatch status, and transplant indication. The pre-transplant fungal colonization cohort had 4 patients (4.8%) develop any severe fungal infection post-transplant (2 Aspergillus spp. and 2 non-Aspergillus spp.). Pre-transplant fungal colonization was not associated with severe post-transplant fungal infection [RR 1.36 (0.45-4.06)] or with severe post-transplant Aspergillus spp. infection specifically [RR 0.80 (0.18-3.55)]. Unadjusted mortality was also not statistically significant [RR 0.74 (0.47-1.17)]. Conclusions In our cohort of bilateral lung transplant recipients, pre-transplant fungal colonization was not associated with severe post-transplant invasive fungal infection. Although limited by the retrospective nature of the study, the results provide supportive evidence that pre-transplant fungal colonization should not be a precluding factor for undergoing lung transplantation. This abstract is funded by: None
Influence of brief carbon dioxide inhalation on acute exercise performance and recovery: A pilot study
Abstract Brief inhalation of carbon dioxide (CO 2 ) has been proposed to counteract transient hypocapnia by enhancing oxygen unloading, vasodilation, and sympathetic modulation. Despite these potential ergogenic mechanisms, CO 2 has rarely been investigated in the exercise context. The present study investigated whether brief CO 2 inhalation (iCO 2 ) influences performance and recovery during high‐intensity interval exercise. Nine healthy adults completed two randomized, single‐blinded crossover trials of repeated cycling intervals at 85% peak work rate until volitional exhaustion or cadence dropped below 60 rpm, with a minimum 2‐min interval duration required and 3‐min active recovery between bouts. Participants inhaled 5% CO 2 or room air (15 breaths) before and after each exercise bout. Gas exchange, cardiovascular responses, and perceived exertion were assessed. Total exercise time was similar between trials; however, participants completed more intervals with iCO 2 . During the first interval, iCO 2 increased exercise duration and VO 2 . At matched exercise time, perceived exertion and dyspnea were lower with iCO 2 . During recovery, systolic blood pressure was lower and heart rate was higher following iCO 2 . Brief iCO 2 improved first‐interval performance, altered cardiovascular recovery, and reduced perceptual strain but did not extend overall exercise duration. These findings suggest iCO 2 may transiently modulate tolerance and autonomic‐vascular responses during high‐intensity interval exercise.
Elective genomic sequencing for adults in research, clinical and commercial contexts
Abstract Purpose Elective genomic sequencing (EGS) returns monogenic disease findings in multiple genes, including potentially novel variants, and may also provide participants with carrier status, pharmacogenomic and other health-related information. The PeopleSeq Study assessed participants’ motivations for and concerns about EGS and the associated clinical and psychosocial outcomes across diverse EGS providers. Methods We administered a shared questionnaire to participants who chose to undergo EGS via 18 academic, clinical, or commercial EGS platforms. Results We enrolled 1575 participants, of whom 1147 (72.8%) completed a questionnaire after receiving their EGS results. A majority (60.3%) of the participants who completed a post-result questionnaire self-reported receiving results they assessed as important, including negative findings, and 75.9% reported a form of health-related utility. Among a subset (19.4%) who shared their EGS reports, 16.6% (37 of n =223) received a monogenic finding and self-reported results deemed “important” were consistent with EGS reports. Most participants (74.1%) discussed their results with their family, but fewer discussed their results with a healthcare provider other than the site team (41.7%) or had one or more medical visits as a direct result of their EGS testing (23.1%). Participants expressed diverse motivations for EGS, with 91.4% expressing interest in their personal disease risk and 54% who expressed quasi-indication-based motivations related to family medical history. Individuals motivated by family history reported important results at a significantly higher rate. Conclusions Early adopters of EGS are motivated by general interest in their health as well as quasi-indication-based considerations such as family history. A majority of participants learned results they considered medically important, but a much smaller segment engaged healthcare providers with their results.
Can Hybrid PET/MRI Advance Precision Imaging in Cardiomyopathy?
A Systematic Review of Post-Procedural Rehabilitation Protocols following Percutaneous Needle Tenotomy and Ultrasonic Debridement for Gluteal, Proximal Hamstring, and Patellar Tendinopathy
American Journal of Physical Medicine & Rehabilitation | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Objective: Percutaneous needle tenotomy (PNT) and ultrasonic debridement (UD) are minimally invasive interventions for the management of chronic tendinopathy. Despite their increasing use, no standardized, evidence-based rehabilitation guidelines currently exist to direct clinicians in post-procedural management. This systematic review aimed to characterize and synthesize reported rehabilitation protocols following PNT and UD for patellar, proximal hamstring, and gluteal tendinopathies. Design: Systematic Review Results: Twenty-seven studies met inclusion criteria, with patellar tendon procedures (n=13) being the most common, followed by gluteal (n=6), proximal hamstring (n=3), and multi-tendon protocols (n=5). Of the included studies, 21 (78%) utilized percutaneous needle tenotomy (PNT) and six (22%) used ultrasound debridement or Tenex. Exercise restrictions were mandated in 19 studies (70%), while 12 (44%) provided a detailed, structured rehabilitation program, frequently emphasizing eccentric loading for patellar and hamstring tendons. Weight-bearing limitations were uncommon, appearing in only three studies (11%). Fifteen studies (56%) combined the procedure with platelet-rich plasma (PRP). Pharmacological protocols also showed high variance, with NSAID restrictions ranging from 1 to 28 days and corticosteroid avoidance lasting between 10 days and one year. Overall, substantial variability remains regarding recommended activity progression, exercise initiation, and mechanical loading strategies across current research. Conclusion: PNT and UD appear effective for managing refractory tendinopathy, yet post-procedure rehabilitation guidelines remain inconsistent and supported by limited high-quality evidence. Future research should aim to identify key variables that guide individualized rehabilitation progressions, optimizing recovery timelines, and facilitating safe and efficient return to activity following PNT and UD procedures.
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly influenced by stage at initial presentation. Generally, localized disease and smaller primary tumors have been associated with more favorable prognosis. Thus, the select content featured in this issue focuses on risk factors associated with cutaneous melanoma development and which should be considered during an initial assessment. These include (1) phenotypic predispositions, (2) personal medical history or comorbidities, (3) genetic predispositions, and (4) environmental factors.